CADL NASDAQ
Candel Therapeutics, Inc.
1W: -11.0%
1M: +8.0%
3M: +55.2%
YTD: +45.8%
1Y: +34.2%
3Y: +401.9%
$7.99
+0.06 (+0.76%)
After Hours: $8.50 (+0.51, +6.38%)
Weekly Expected Move ±12.9%
$7
$8
$9
$10
$11
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
3 bullish
0 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (23)
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating
10 Health Care Stocks Moving In Friday's Intraday Session
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of “Hold” by Brokerages
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives $18.00 Average Target Price from Brokerages
Candel gains on additional mid-stage trial data for lead asset
FY2030 Earnings Forecast for CADL Issued By HC Wainwright
Candel Therapeutics GAAP EPS of -$0.54
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Paul Manning Buys 550,458 Shares of Candel Therapeutics (NASDAQ:CADL) Stock
Candel Therapeutics prices $100M public offering
Why Is Candel Therapeutics Stock Falling Friday?
Candel Therapeutics prices $100M public offering at $5.45 per share
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of “Moderate Buy” from Analysts